We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-1.23%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$145M
Cap. Flow
+$20.1M
Cap. Flow %
0.74%
Top 10 Hldgs %
78.13%
Holding
30
New
1
Increased
8
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$37M
2
MGNX icon
MacroGenics
MGNX
+$11.7M
3
JUNO
Juno Therapeutics, Inc.
JUNO
+$11.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$6.12M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$49.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$9.89M
3
PTCT icon
PTC Therapeutics
PTCT
+$5.25M

Sector Composition

Rank Sector Weight
1 Healthcare 91.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
26
Novavax
NVAX
$1.31B
$10.5M 0.39%
416,500
– –
PTCT icon
27
PTC Therapeutics
PTCT
$6.12B
$7.45M 0.28%
682,912
-500,000
-42% -$5.25M
PBYI icon
28
Puma Biotechnology
PBYI
$454M
$7.43M 0.28%
241,991
– –
ACHN
29
DELISTED
Achillion Pharmaceuticals
ACHN
$5.28M 0.2%
1,279,340
– –
CEMP
30
DELISTED
Cempra, Inc.
CEMP
– –
-2,041,900
Closed -$49.4M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2016 Portfolio in Review

As of Q4 2016, BB Biotech held 30 positions worth $2.7B, down 5.1% from $2.84B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

BB Biotech's Q4 2016 filing shows 1 new, 8 increased, 2 reduced and 1 closed positions. Its largest new stake was Myovant Sciences Ltd.: 3,192,835 shares worth $39.7M. The largest sale was Cempra, Inc., an estimated $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

  • BB Biotech's largest Q4 2016 buy was Myovant Sciences Ltd.: 3,192,835 shares worth $39.7M.
  • BB Biotech added most to MacroGenics in Q4 2016, an estimated $11.7M increase.
  • BB Biotech's biggest Q4 2016 reduction was Ionis Pharmaceuticals, cutting an estimated $9.89M.
  • BB Biotech fully exited Cempra, Inc. in Q4 2016, selling an estimated $49.4M.
  • BB Biotech's ten largest holdings make up 78% of its $2.7B portfolio in Q4 2016.
  • BB Biotech opened 1 new position and closed 1 in Q4 2016.
  • BB Biotech's portfolio value fell 5.1% quarter-over-quarter to $2.7B.

Based on BB Biotech's 13F filing for Q4 2016, filed 14 Feb 2017.